Courtesy of NIDA

A National Institutes of Health-funded study found that treatment of opioid use disorder with either methadone or buprenorphine following a nonfatal opioid overdose is associated with significant reductions in opioid related mortality. The research, published today in the...

A special issue of the journal Developmental Cognitive Neuroscience features more than a dozen articles related to the Adolescent Brain Cognitive Development (ABCD) Study, a landmark study on brain development and child health led by the National Institute on Drug Abuse (NIDA), part of the...

Courtesy of University of Michigan

The complete volume of the 2017 Monitoring the Future Survey (MTF) teen drug use and behavior survey results is now available online with never before seen highlights about drug use and attitudes among the nation’s eighth, 10th and 12th graders. New...

A project that identified and tested a bioinformatics program that can help identify underreported suicides linked to drug overdoses was awarded the first-place distinction at the 2018 Intel International Science and Engineering Fair (ISEF)—the world’s largest science competition for high school...

Courtesy of US WorldMeds, LLC.

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, is pleased to announce that lofexidine, the first medication for use in reducing symptoms associated with opioid withdrawal in adults, has been approved by the U.S. Food and...

​Fluorescence micrograph of a neuronal cell body showing the location of opioid receptor activation detected by the new biosensor immediately before (left panel) and 20 seconds after (right panel) application of morphine. Arrow points to the Golgi apparatus, a location within the interior of the...